Latest News

STAT Plus: Fibrogen discloses new data that eases heart-safety concerns about experimental anemia pill

Fibrogen presented new clinical trial data on Friday that alleviates concerns about the heart safety of its experimental anemia pill, the drugmaker said.

A pooled safety analysis of approximately 8,000 kidney disease patients enrolled in six Phase 3 clinical trials concluded that the risk of an adverse cardiovascular event — heart attacks, strokes, death, and chest pain — was statistically comparable between the Fibrogen drug called roxadustat and either a placebo or a currently approved anemia injection used as a control.

Continue to STAT Plus to read the full story…

Source link

Related posts

How Philly can grow the next generation of leading biotech startups


White House expected to recommend Americans wear cloth masks to prevent coronavirus spread


New algorithm could help investigate the genetic clues behind immunity


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy